SuperworthCryo Cell International EPS CCEL
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Aug 31, 2026
- −$0.23
- Latest quarter, Q3 FY26
- $0.16
- +78% on a year earlier
- Fiscal year 2025
- −$0.31
- −720% on the year before
Cryo Cell International's earnings per share was −$0.23 over the twelve months to Aug 31, 2026.
In its latest quarter, Q3 FY26, it was $0.16, up 78% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.31 | −720% |
| FY2024 | $0.05 | n/a |
| FY2023 | −$1.15 | −448% |
| FY2022 | $0.33 | +32% |
| FY2021 | $0.25 | −44% |
| FY2020 | $0.45 | +67% |
| FY2019 | $0.27 | n/a |
| FY2018 | −$0.15 | −150% |
| FY2017 | $0.30 | n/a |
| FY2016 | −$0.17 | −120% |
| FY2015 | $0.83 | +1560% |
| FY2014 | $0.05 | n/a |
| FY2013 | $0.00 | n/a |
| FY2012 | −$0.56 | n/a |
| FY2011 | −$0.18 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $0.16 | +78% | −$0.23 | |
| Q2 FY26 | $0.07 | +75% | −$0.30 | |
| Q1 FY26 | $0.01 | −67% | −$0.33 | |
| Q4 FY25 | −$0.47 | n/a | −$0.31 | |
| Q3 FY25 | $0.09 | −31% | −$0.07 | |
| Q2 FY25 | $0.04 | −50% | −$0.03 | |
| Q1 FY25 | $0.03 | −57% | $0.01 | |
| Q4 FY24 | −$0.23 | n/a | $0.05 | |
| Q3 FY24 | $0.13 | +63% | −$1.07 | |
| Q2 FY24 | $0.08 | +167% | −$1.12 | |
| Q1 FY24 | $0.07 | −22% | −$1.17 | |
| Q4 FY23 | −$1.35 | −1450% | −$1.15 |
Against its peers
Companies in Healthcare nearest Cryo Cell International's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CCELCryo Cell International | −$0.23 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cryo Cell International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.